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Abstract
Background: Epithelial-Mesenchymal Transition (EMT) plays an important role in cancer 
progression and metastasis. We investigated the expression of two EMT-related molecules, 
ZEB-1 and E-cadherin, in invasive ductal breast carcinoma and evaluated their association with 
clinicopathological parameters and recurrence-free survival.
Methods: We evaluated the expression of ZEB-1 and E-cadherin in 116 patients of Stage I, II, and 
III primary invasive ductal breast carcinoma (mean age, 58.5 years, male: female = 0:116) using 
immunohistochemistry. 
Results: Of the 116 patients, 51 (44%) had Stage I, 58 (50%) had Stage II,　and 7 (6%) had Stage III 
tumors. Thirty seven patients (32%) had lymph node metastasis. One hundred and one patients (87%) 
had ER positive tumors, and 20 patients (17%) had HER2 positive tumors. Positive ZEB-1 expression 
was observed in the tumors of 66 patients (57%), but it was not significantly associated with 
clinicopathological parameters. Reduced E-cadherin expression was observed in the tumors of 34 
patients (29%). It was significantly associated with negative estrogen receptor expression. Patients 
with a positive ZEB-1 and / or reduced E-cadherin had a poorer outcome than the other patients in 
terms of recurrence-free survival.
Conclusion: ZEB-1 and E-cadherin expression may predict recurrence-free survival in patients with 
invasive ductal breast carcinoma. 
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Introduction
　Breast cancer is one of the most common 
m a l i g n a n t  c a n c e r  i n  w o m a n  w o r l d w i d e . 
Approximately 90 % of breast cancer-related deaths 
are caused by local invasion and distant metastasis 
of tumor cells. Metastasis is a complex process 
divided into a number of steps including detachment 
of tumor cells from the primary tumor, invasion, 
migration, intravasation, survival in vasculature, 
extravasaion, and colonization of the secondary 
site. The transformation of normal breast cancer 
epithelial cells to metastatic ones arises during the 
metastatic cascade1). The pioneering work of Hay2) 
first described Epithelial-Mesenchymal Transition 
(EMT). That is a phenomenon that epithelial cells 
transform to mesenchymal cells. EMT plays crucial 
role in the organogenesis of embryo. In addition, 
EMT also allows epithelial tumor cells to lose their 
attachments to neighboring cells and transit to 
mesenchymal tissue. EMT contributes to cause 
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organ fibrosis and promote carcinoma progression 
through a variety of mechanisms. Recently, it has 
become clear that EMT also plays an important 
role in cancer progression, metastasis, and 
chemoresistance3, 4). The involvement of EMT varies 
between different types of cancers. Although 
investigations about breast cancer had been 
performed, much remains to be elucidated 1, 5).  
　E-cadherin is a transmembrane glycoprotein 
which is mainly presented in human epithelial cells 
and mediates cell adhesion between E-cadherin 
molecules on adjacent cells. It is one of a typical 
adhesive molecules of epithelium and plays a role 
of establishment of stable adherent junctions 
and adhesion of cells. During EMT, expression 
of E-cadherin is decreased, then epithelial tumor 
cells lose their adhesion and become migratory 
and invasive acquiring mesenchymal properties. 
It is known that tumor malignancy is inversely 
correlated with its expression. Now it is considered 
that the most important event of EMT is loss of 
E-cadherin3, 4). Various transcriptional factors 
regulate expression of E-cadherin. Zinc finger 
E-box-binding homeobox 1 (ZEB-1) is a member 
of the zinc-finger E-box-binding homeobox factor 
family, and can inhibit the expression of E-cadherin 
by binding to its promoter.  ZEB-1 is  now 
considered a one of the typical molecule of EMT 
by inhibiting E-cadherin expression which induce 
an epithelial phenotype 6, 7). EMT molecules induce 
changes in morphology of mammary epithelial 
cells with the shift to mesenchymal phenotype, and 
acquiring malignancy and chemoresistance 8). Many 
previous studies have evaluated ZEB-1 expression 
in several carcinomas such as gastric, pancreatic, 
hepatocellular, and lung cancers, and reported that 
the ZEB-1 expressions were associated with high 
malignancy, development of metastasis and poor 
prognosis 9-12).   
　Postoperative recurrence is the key factor 
affecting the clinical treatment and prognosis 
of breast cancer patients. We hypothesized that 
EMT related molecules could be predictive factors 
of postoperative recurrence of invasive ductal 
breast cancer. Although ZEB-1 expression in 
breast cancer has previously been studied using 
immunohistochemistry 13-16), it is still not clear 
whether ZEB-1 predicts recurrence-free survival 
in patients with invasive ductal breast carcinoma. 
In this study, we investigated the association 
between the expression status of the EMT related 
molecule, ZEB-1 and E-cadherin, and postoperative 
recurrence in invasive ductal breast carcinoma 
using immunohistochemistry.  
Material and methods
Patients and tumor samples
　We evaluated 116 patients of Stage I, II, and III 
primary invasive ductal breast carcinoma who had 
undergone curative surgery between 2007 and 2010 
at Yamagata University Hospital. All specimens 
were histologically diagnosed as invasive ductal 
breast carcinoma on the basis of the General Rules 
for Clinical and Pathological Recording of Breast 
Cancer (The Japanese Breast Cancer Society, 2012, 
17th edition). Staging was determined according 
to the TNM Classification of Malignant Tumours 
(UICC, Seventh Edition, 2009). For bilateral breast 
carcinomas, we recorded the side of higher stage 
or malignancy. We used cancer stage recorded at 
admission if neo adjuvant chemotherapy had been 
performed. 
　Estrogen receptor (ER) and progesterone receptor 
(PgR) were detected by immunohistochemical 
staining with anti-estrogen receptor rabbit 
monoclonal antibody (clone SP1, Ventana Japan, 
Yokohama, Japan) and anti-progesterone receptor 
rabbit monoclonal antibody (clone 1E2, Ventana 
Japan, Yokohama, Japan), respectively. They were 
defined as positive if at least 1% of the tumor cells 
showed positive immunohistochemical staining. 
Human epidermal growth factor receptor type 
2 (HER2) was detected by immunohistochemical 
staining using the Hercep Test kit (DAKO JAPAN, 
Tokyo, Japan). HER2 positivity was defined as 
immunohistochemical score of 3 or 2 which is 
fluorescence in situ  hybridization (FISH) positive. 
　This study was conducted according to principals 
of the Declaration of Helsinki, with approval from 
the ethic committees of Yamagata University 
Faculty of Medicine. Before tissues were obtained, 
each patient provided written informed consent to 
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participate in our study. In our institute during 
the period of this study, we selected each patients’ 
treatment according to patients’own risk and the 
clinical practice guidelines used at that time, and 
any treatments were not performed if they were 
contraindicated or the patient did not consent to 
them.
Immunohistochemistry 
　A mouse anti-human monoclonal antibody 
to ZEB-1 (Clone CL0151, lot number 02551) was 
purchased from ATLAS ANTIBODIEDS, Inc. 
(Stockholm, Sweden), and a mouse anti-human 
monoclonal antibody to E-cadherin (Clone NCH-38, 
lot number 10081325) was purchased from DAKO 
JAPAN (Tokyo, Japan). These were diluted to 
1:500 and 1:100, respectively, in phosphate-buffered 
saline (PBS) according to the manufacturer’s 
instructions.
　Each resected specimen was fixed with formalin 
and embedded in paraffin. Thin serial sections 
containing representative areas of invasive 
carcinomas were made with a microtome. 
Immunohistochemical staining was performed 
using the labeled streptavidin biotinylated 
antibody (LSAB) method. After deparaffinization 
and dehydration, heat-induced antigen retrieval 
by autoclave pretreatment (120℃ for 20 minutes) 
in citrate buffer solution (pH 6.0) was performed. 
Endogenous peroxidase activity was blocked using 
absolute methanol solution containing 0.3% H2O2 
for 30 minutes. Unspecific staining was blocked 
by skimmed milk. Specimens were incubated 
with diluted anti-ZEB-1 or E-cadherin antibodies 
at 4℃ overnight. These antibodies were omitted 
for negative controls. Next day, specimens were 
incubated with a biotinylated secondary antibody 
and an avidin-biotin-peroxidase complex, SAB-
PO (MULTI) kit purchased from NICHIREI 
(Tokyo, Japan). Biotin was visualized using 
diaminobenzidine (DAB). Counterstaining was 
performed using hematoxylin. We used uterine 
carcinosarcoma specimens as positive control for 
ZEB-1 staining, and normal colonic mucosa as 
positive control for E-cadherin staining. There was 
no staining in the negative controls.
Evaluation of immunohistochemical staining
　Based on a previous study by Soini 15), the 
immunoreactivity for ZEB-1 of stromal fusiform 
cells was semi-quantified as follows:
0-5% = negative, 5-25% = weak positivity, 25-50% = 
moderate positivity, 50-75% = strong positivity, 75-
100% = very strong positivity
We considered that staining of weak positivity 
or over was significant positive, intensity was 
not evaluated. For epithelial tumor cells, only the 
presence of nuclear negativity or positivity was 
assessed. According to Pang’s previous report17), 
the immunoreactivity of E-cadherin of epithelial 
tumor cells was semi-quantified as follows:
Intensity of staining was categorized into four 
grades (0 to 3);
0, no staining; 1, weak staining; 2, moderate 
staining; 3, strong staining. 
In addition, we compared the peripheral part of 
the tumor, such as infiltrating fatty tissue, with 
the central part of the tumor. We considered 
E-cadherin expression to be reduced if whole tumor 
cells were weak staining, or if the peripheral part 
of the tumor were stained less than the central 
part of the tumor. We verified that normal ductal 
tissue showed moderate or greater staining as an 
internal positive control.
Statistical analysis
　 W e  u s e d  t h e  J M P  1 1 . 0 . 0  s o f t w a r e  f o r 
Windows (SAS Japan, Tokyo, Japan) for all 
statistical  analyses.  Associations between 
ZEB-1 or E-cadherin expression status and 
clinicopathological parameters were evaluated 
using the Chi squared test. Recurrence-free 
survival rates were evaluated by Kaplan-Meier 
method and differences were evaluated using the 
log-rank test. The time to recurrence was defined 
as the duration from the original operation to 
the date on which patients were diagnosed with 
recurrence based on the radiological findings. 
Prognostic factors were analyzed using univariate 
and multivariate analyses (Cox proportional 
hazard model). A P-value of less than 0.05 was 
considered statistically significant. 
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Results
Characteristics of patients
　Characteristics of patients are summarized in 
Table1. There were no male patients in the period 
of this study. All of the patients were female, 
and their mean age was 58.5 years (range 32-88). 
Fifty one patients (44%) had Stage I disease, 58 
patients (50%) had Stage II disease, and 7 patients 
(6%) had Stage III disease. Thirty seven patients 
(32%) had lymph node metastasis. One hundred 
and one patients (87%) had ER positive tumors, 
and 20 patients (17%) had HER2 positive tumors, 
and 9 patients (8%) had triple negative tumors. 
None of the patients died in the perioperative 
period. During the median follow-up period of 59.5 
months (range 8-89) from surgery to recurrence, 
12 patients experienced postoperative recurrence (7 
in the lymph nodes, 4 in the bone, 3 in the lung, 1 
in the liver; and in some cases the disease recurred 
simultaneously at several sites). Of the 12 recurrent 
patients, the median time from surgery to 
recurrence was 20.5 months (range 12-43). During 
the median follow-up period of 61 months (range 
8-89) from surgery to the most recent follow-
up, 5 patients died from the disease. Of the 5 died 
patients, the median time from recurrence to death 
was 24 months (19-68). 
ZEB-1 expression
　In the positive control, ZEB-1 staining was 
detected in the nuclei of sarcoma lesion of uterine 
carcinosarcoma (Fig. 1 a). ZEB-1 expression was 
detected only in the nuclei of stromal fusiform 
cells surrounding the invasive ductal breast 
carcinomas (Fig. 1 b). Only a few nuclei of 
stromal fusiform cells surrounding non-invasive 
carcinomas were stained. No epithelial tumor 
Fig. 1　Representative images of ZEB-1 staining. Original magnification, × 20
a 　Uterine carcinosarcoma as a positive control; Tumor cells in the sarcoma lesion were stained. 
b 　Stromal fusiform cells in invasive ductal breast carcinoma were stained.
c 　ZEB-1 expression in the marginal lesion of tumor.
Table 1.  Characteristics of patients
Patients n = 116
Sex, n (%) 
Male/Femal 0 (0%) / 116 (100%)
Age 58.5 ± 13.3 (32 - 88)
T classification 
   T1/T2/T3/T4 62 (54%)/ 45 (39%)/ 4 (3%)/ 5(4%)
Lymph node metastasis 
   Positive 37 (32%)
   Negative 79 (68%)
TNM Stage 
   I/II/III 51 (44%) / 58 (50%)/7 (6%)
ER 
   Potitive 101 (87%)
  Negative 15 (13%)
PgR 
  Potitive 86 (74%)
  Negative 30 (26%)
HER2 
  Potitive 20 (17%)
  Negative 96 (83%)
Triple negative 9 (8%)
Menoposal status 
  Pre 34 (29%)
  Post 82 (71%)
Operation 
   Mastectomy 64 (45%)
   Conservative surgery 52 (55%)
Axillar disection 
   Axillar 105 (91%)
   Sentinel node biopsy 7 (6%)
   None 4 (3%)
Systemic therapy 
   Chemothrapy  45 (39%)
   Trastuzumab 9 (8%)
   Hormonal therapy 100 (86%)
   None 5 (4%)
Radiation 36 (31%)
Recurrence 
   Present 12 (10%)
Died 5(4%)
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cell was stained. Therefore, we only evaluated 
expression in the stromal fusiform cells. Table 2 
shows the associations between ZEB-1 expression 
and clinicopathological parameters. Positive 
expression of ZEB-1 in stromal fusiform cells was 
observed in 66 patients (57%). It was significantly 
associated with postoperative recurrence (p = 0.04). 
There was no significant association between ZEB-
1 expression and other parameters including stage, 
lymph node metastasis and biomarkers. ZEB-
1 expression in the marginal lesion of a tumor 
as if it was starting invasion was observed in 7 
patients (Fig. 1c). But this was not significantly 
associated with clinicopathological parameters or 
postoperative recurrence (date not shown).
E-cadherin expression
　E-cadherin staining was detected in the cellular 
membrane of epithelial tumor tissues, and 
intensities of staining were shown in Fig. 2. We 
also show an example that the peripheral part of 
tumor such as tumor infiltration to fatty tissue 
Fig. 2
Immunohisitochemical analysis of E-cadherin 
expression. 
Original magnification, × 20. Examples of positive 
staining of membranes in breast cancer tissue: a 
strong, b moderate, c weak; d weak staining in 
peripheral part.
Table 2. Clinicopathological parameters of stromal ZEB-1 and tumor E-cadherin expression in breast 
invasive ductal carcinoma.
  ZEB-1    E-cadherin  
Variable Total no. positive negative p-value  preserved reduced p-value
 (n = 116) (n = 66) (n = 50)   (n = 82) (n = 34) 
Stage, n (%)        
  I  25 (38%) 26 (52%) 0.28  38 (46%) 13 (38%) 0.705
  II  36 (54%) 22 (44%)   39 (48%) 19 (56%) 
  III  5 (8%) 2 (4%)   5 (10%) 2 (6%) 
Lymph node        
  Positive  25 (38%) 12 (24%) 0.109  23 (28%) 14 (41%) 0.172
  Negative  41 (62%) 38 (76%)   59 (72%) 20 (59%) 
ER        
  Positive  56 (85%) 45 (90%) 0.408  76 (93%) 25 (77%) 0.008
  Negative  10 (15%) 5 (10%)   6 (7%) 9 (23%) 
PgR        
  Positive  46 (70%) 40 (80%) 0.201  63 (77%) 23 (67%) 0.31
  Negative  20 (30%) 10 (20%)   19 (23%) 11 (33%) 
HER2        
  Positive  15 (23%) 5 (10%) 0.065  14 (17%) 6 (18%) 0.941
  Negative  51 (77%)  45 (90%)   68 (83%) 28 (82%) 
Triple negative        
  Yes  5 (8%) 4 (8%) 0.932  2 (2%) 7 (21%) 0.002
  Other  61 (92%) 46 (92%)   80 (98%) 27 (79%) 
Recurrence        
  Absent  56 (85%) 48 (96%) 0.04  78 (95%) 26 (76%) 0.004
  Present  10 (15%) 2 (4%)   4 (5%) 8 (24%) 
ZEB-1        
  Positive      42 (51%) 24 (71%) 0.052
  Negative      40 (49%) 10 (29%) 
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was stained less than the central part of tumor (Fig. 
3). Table 2 also shows the associations between 
E-cadherin expression and clinicopathological 
parameters. Reduced E-cadherin expression was 
observed in the tumor of 34 patients (29%). It was 
significantly associated with ER negative (p = 
0.008), triple negative (p = 0.002) and postoperative 
recurrence (p = 0.004) .  As with ZEB-1,  no 
significant association was observed with other 
factors including stage, lymph node metastasis. 
Positive ZEB-1 expression occurred more frequently 
in tumors with reduced E-cadherin expression, but 
this was not significant (p =0.052). 
Recurrence-free survival
　During the median follow-up period of 59.5 
months (range 8-89), 12 patients experienced disease 
recurrences, of whom 10 patients had tumors with 
positive for ZEB-1 expression, and 8 had tumors 
of reduced E-cadherin expression. Figure 4 shows 
recurrence-free survival rate after resection by 
Kaplan-Meier curve according to ZEB-1, E-cadherin 
expression or matching them. The patients with 
positive ZEB-1 expression group had a poorer 
outcome in terms of recurrence-free survival than 
the negative ZEB-1 expression group (5-year 83.2% 
vs. 95.8%, p = 0.036) (Fig. 4a). Similarly, the reduced 
E-cadherin expression group had a poorer outcome 
than the preserved E-cadherin expression group 
(5-year 74.5% vs. 94.7%, p = 0.002) (Fig. 4b). Among 
patients with positive ZEB-1 expression, reduced 
E-cadherin group had a poorer outcome than the 
Fig. 3
An example comparing the peripheral part of 
tumor with the central part of tumor of E-cadherin 
expression.
Fig. 4
Kaplan-Meier curves of recurrence-free survival for each immunohistochemical staining group;
a.the ZEB-1 positive group vs. the ZEB-1 negative group (5-year 83.2% vs. 95.8%, p = 0.036). b. the E-cadherin 
negative group vs. the E-cadherin positive group (5-year 74.5% vs. 94.7%, p = 0.002). c. among ZEB-1 positive 
groups, the E-cadherin reduced group vs. the E-cadherin preserved group (5-year 68.2% vs. 91.8%, p = 0.016). 
d. the ZEB-1 positive/ E-cadherin reduced group vs. the other group (5-year 68.2% vs. 94.1%, p = 0.003).
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other group (5-year 68.2% vs. 91.8%, p = 0.016) (Fig. 
4c). The positive ZEB-1 and reduced E-cadherin 
group had a poorer outcome than the other group 
(5-year 68.2% vs. 94.1%, p = 0.003) (Fig. 4d).
Univariate and multivariate analyses
　The prognostic factors relating to recurrence-
free survival were evaluated using univariate 
and multivariate analyses (Table 3). Univariate 
analyses showed that tumor size > 2.0 cm (p 
=0.0003), HER2 positive (p = 0.027), lymph node 
metastasis (p = 0.009), positive ZEB-1 expression 
(p = 0.027), and reduced E-cadherin expression (p = 
0.004) were significantly related to recurrence-free 
survival. Multivariate analyses showed that tumor 
size > 2.0 cm (p = 0.011) and reduced E-cadherin 
expression (p = 0.045) were independent factors for 
recurrence-free survival. Lymph node metastasis 
had borderline significance (p = 0.052). 
Discussion 
　We investigated the relationship between the 
expression of the EMT related molecules ZEB-
1 and E-cadherin, and postoperative recurrence-
free survival of invasive ductal breast carcinoma 
patients. Recurrence-free survival rates were 
significantly lower in the group of positive ZEB-1 
and reduced E-cadherin. 
ZEB-1
　Montserrat et al. 14) previously reported that 19 
% of specimen of invasive breast carcinoma had 
positive ZEB-1 expressions in epithelial tumor cells 
using immunohistochemistry, but its expression 
was not related with prognosis. Surprisingly 
down-regulation of ZEB-1 gene expression was 
related with poor overall survival and disease-
free survival. Soini et al. 15) reported that 75 % 
of specimens of breast carcinomas had positive 
ZEB-1 expression in stromal fusiform cells using 
immunohistochemistry, but no epithelial tumor 
cells had positive expression. They also reported 
that ZEB-1 expression in stromal fusiform cells did 
not related with prognosis. In our study, positive 
ZEB-1 expression using immunohistochemistry 
was detected in the nuclei of fusiform cells 
surrounding the invasive ductal breast carcinomas 
and we observed positive ZEB-1 expressions in only 
a few nuclei of stromal fusiform cells surrounding 
non-invasive carcinoma lesions contained in the 
specimen of this study (data not shown). We used 
uterine carcinosarcoma as a positive control, and 
in this sample, ZEB-1 expression was observed 
only in the sarcoma lesion, and no expression 
in the carcinoma lesion. We also observed ZEB-
1 expressions in some colonic carcinomas, no 
epithelial tumor cells showed positive staining (data 
not shown). Recent studies have shown that cells 
experience drastic shape changes from epithelial 
cells to a spindle-like shape of mesenchymal cells, 
and a portion of myofibroblasts within fibrotic 
lesion arise from epithelium during EMT18). The 
fusiform cells which we detected positive ZEB-1 
expression might be derived from epithelial tumor 
cells and associated with tumor malignancy. We 
also observed ZEB-1 expression in the marginal 
lesion of tumors in 7 of the 116 patients. We 
named it Kimura.W-Shibata.K type infiltration. 
These were presumed to be undergoing EMT 
and infiltration, but these were not significantly 
associated with clinicopathological parameters 
or postoperative recurrence. Further studies are 
needed to verify the associations.  
Table 3. Univariate and multivariate analyses of recurrence-free survival using Cox proportional hazard 
model.
  Univariate    Multivariate  
Variables  Hazard ratio 95%CI p-value  Hazard ratio 95%CI p-value
Tumor size  > 2cm 14.75  2.87-269.53 0.0003  8.24 1.50-153.88 0.011 
HER2 positive  4.03  1.19-12.66 0.027  2.17 0.65-8.45 0.213 
Lymph node metastasis 4.66  1.47-17.46 0.009  3.58 0.99-12.56 0.052 
positive ZEB-1  4.42  1.16-28.72 0.027  2.32 0.53-16.08 0.280 
reduced E-cadherin 5.37  1.69-20.15 0.004  3.62 1.03-15.05 0.045 
CI, confidence interval
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E-cadherin
　There are many studies about E-cadherin 
e x p r e s s i o n  o f  b r e a s t  c a n c e r s  u s i n g 
immunohistochemistry and the meta-analysis 
has been performed. However many of these 
s tud ies  reported  that  loss  o f  E-cadher in 
expression might be an independent negative 
prognostic indicator for infiltrating ductal 
br eas t  car c inoma ,  immunoh i s to chemica l 
techniques and interpretation algorithms have 
not been standardized 19). Recently, some studies 
evaluated E-cadherin expression in whole tumor 
cells17, 20). If the staining of whole tumor cells is 
uniformly weak, it is possible that the results are 
influenced by preservation of the specimens or 
immunohistochemical techniques. We presumed 
that loss of E-cadherin initially occurs in the 
peripheral part of tumor, so we evaluated not 
only whole tumor cells, but also the peripheral 
part of tumors comparing with the central part of 
tumors. We also verified that normal breast tissue 
in the same specimens were stained properly and 
loss of E-cadherin was observed in only tumor 
tissues. Although these evaluations performed 
as accurately as possible due to differences in 
each specimen, we could improve the precision of 




　In this study, although the patients with positive 
ZEB-1 expression and the reduced E-cadherin had 
a lower recurrence-free survival rate, they are 
not sufficiently useful predictive factors alone. 
We evaluated the recurrence-free survival rate by 
matching them. The positive ZEB-1 and reduced 
E-cadherin group had a lower recurrence-free 
survival rate than the other group (5-year 68.2 vs. 
94.1%, p = 0.0003). We propose that the combination 
of ZEB-1 and E-cadherin expression could be a 
more useful predictive factor in invasive ductal 
breast carcinoma.
Multivariate analysis
  We evaluated prognostic factors by multivariate 
analyses. Only tumor size > 2.0 cm and reduced 
E-cadherin expression were significant factors. 
Positive ZEB-1 expression was not significant 
in multivariate analyses. We also evaluated 
E-cadherin expression with the new criterion 
comparing expression of the peripheral part of 
tumors with the central part of tumors. We could 
show that reduced E-cadherin expression was a 
significant and independent prognostic factor of 
postoperative recurrence of invasive ductal breast 
carcinoma based on this criterion. We concluded 
that reduced E-cadherin expression was a better 
predictor of postoperative recurrence than positive 
ZEB-1 expression. 
　As far as we know, this is the first study 
of invasive ductal breast carcinoma which 
ident i f i ed  the  combinat ion  of  ZEB-1  and 
E-cadherin expression as a predictive factor in 
terms of recurrence-free survival rate using 
immunohistochemistry. We should consider 
that the patients of positive ZEB-1 and reduced 
E-cadherin expression are at higher risk of 
recurrence and require more aggressive adjuvant 
therapies. Although many studies have reported 
the malignant significance and prognostic value 
of ZEB-1 and E-cadherin, no drugs or treatment 
procedures have been established which are 
targeted to them. Innovations are required to 
establish new therapeutic strategies. A limitation 
of this study is that neither the expression of ZEB-
1 nor E-cadherin were significantly associated with 
overall survival rate. Of the 116 patients, only 5 
patients died during our follow up period. Further 
study is needed with larger number of patients and 
longer follow up period.
Conclusions
　Positive ZEB-1 expression in stromal fusiform 
cells and reduced E-cadherin expression in epithelial 
tumor cells are associated with a poorer outcome in 
terms of recurrence-free survival in invasive ductal 
breast carcinoma patients. 
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